ExpreS2ion Biotech will hold an EGM on December 1, 2026, to vote on a technical capital reduction and amendments to the company's articles of association.
The company proposes a capital reduction and articles amendment due to shares trading below quota value, a technical corporate action with neutral expected impact.
ExpreS2ion Biotech Holding AB has summoned shareholders to an extraordinary general meeting on December 1, 2026, to approve a significant capital reduction. The board proposes reducing the share capital by approximately 62.6 million SEK to align the company's capital structure with its current operations, as shares are currently trading below their quota value.
The company is reducing its share capital because its shares are currently trading below their quota value, and the board aims to align the capital structure with the company's current business operations.